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Abstract
Background: Chikungunya virus (CHIKV) is a recently re-emerged arthropod borne virus responsible for a massive outbreak
in the Indian Ocean and India, and extended to Southeast Asia as well as Italy. CHIKV has adapted to Aedes albopictus,a n
anthropophilic mosquito species widely distributed in Asia, Europe, Africa and America. Our objective was to determine the
clinical and biological features of patients at the acute phase of CHIKV infection.
Methods and Findings: A prospective study enrolled 274 consecutive patients with febrile arthralgia recorded at the
Emergency Department of the Groupe Hospitalier Sud-Re ´union between March and May 2006. Three groups were defined:
one group of 180 viremic patients (positive CHIKV RT-PCR), one group of 34 patients with acute post-viremic infection
(negative CHIKV RT-PCR, positive anti-CHIKV IgM and negative IgG), and one group of 46 uninfected patients (negative
CHIKV RT-PCR, anti-CHIKV IgM and IgG). Bivariate analyses of clinical and biological features between groups were
performed. Patients with CHIKV viremia presented typically with asymmetrical bilateral polyarthralgia (96.5%) affecting the
lower (98%) and small joints (74.8%), as well as asthenia (88.6%), headache (70%), digestive trouble (63.3%), myalgia (59%),
exanthems (47.8%), conjunctival hyperhemia (23%) and adenopathy (8.9%). Vertigo, cutaneous dysesthesia, pharyngitis and
haemorrhages were seldom observed. So far unreported symptoms such as chondrocostal arthralgia (20%), entesopathies
(1.6%), talalgia (14%) were also noted. Prurit was less frequent during the viremic than post-viremic phase (13.9% vs. 41.2%;
p,0.001), whereas lymphopenia was more frequent (87.6% vs. 39.4%; p,0.001). Others biological abnormalities included
leukopenia (38.3%), thrombocytopenia (37.3%), increased ASAT and ALAT blood levels (31.6 and 7.3%, respectively) and
hypocalcemia (38.7%). Lymphopenia ,1,000/mm
3 was very closely associated with viremic patients (Yule coefficient 0.82,
positive predictive value 92.3%). Age under 65 was associated with a benign course, as no patients younger than 65 had to
be hospitalized (Yule coefficient 0.78).
Conclusions: The diagnosis of CHIKV infection in acute phase is based on commonly accepted clinical criteria (fever and
arthralgia), however clinical and biological diffrences exist in acute phase depending on whether or not the patient is within
the viremic phase of the infection.
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Introduction
Chikungunya virus (CHIKV) is a positive strand RNA
enveloped alphavirus belonging to the Togaviridae family. CHIKV
was first isolated by R.W. Ross [1] in the Newala district of
Tanzania and is responsible for acute febrile arthralgia in human.
Since 1952, several outbreaks of Chikungunya fever have been
reported in Sub-Saharan Africa, Asia (India, Pakistan, South-East
Asia, Philippines), and the islands of the Pacific Ocean [2].
CHIKV has emerged in the South-Western Indian Ocean region
in the beginning of 2005. Between March 2005 and September
2006, 38.2% of the 785,000 inhabitants of La Re ´union Island
[3,4] were infected. This is the first outbreak recorded on this
territory.
By including all patients referred to the Emergency Department
(ED) with febrile arthralgia, the aim of this study was to describe
prospectively the clinical and biological features of acute CHIKV
infection and identify features to help differentiate CHIKV
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transcription and polymerase chain reaction (RT-PCR) and
serology, we also compared patients in the acute viremic phase
and those in the post-viremic phase. We also investigated co-
infections. Finally, we also identified clinical and biological
markers for severity in acute CHIKV infection patients by
comparing hospitalized patients to those who were not.
Methods
The prospective study was conducted in the ED of the Groupe
Hospitalier Sud Re ´union (GHSR) Regional Hospital. This
hospital’s standards are similar to those found in mainland France.
It receives people living in the Southern part of the Island of La
Re ´union (350,000 inhabitants). The hospital has 1,154 beds and
316 physicians. The ED receives 41,000 patients annually; with
adults being treated for medical and surgical conditions, and
children for surgical conditions only.
We enrolled all patients over 15 years of age referred for febrile
arthralgia at the ED between March 1
st 2006 and May 31
st 2006.
A clinical examination, a blood sampling and a questionnaire were
completed for all included subjects as the time of admission at the
ED. This was the only time those patients were examined and
interrogated for the purpose of this study.
The questionnaire was written after a 2-months observation
period (January to February 2006, when the epidemic was at its
peak, with an incidence of 45,000 cases per week). The
questionnaire was created and validated after the medical file
analysis of 1,030 consecutive patients referred to the ED with
febrile arthralgia evocative of Chikungunya. The data collected
included age, gender, medical history (co-morbidity, recent travels
abroad), symptoms and date of their onset (1
st day), the need for
hospitalization and biological parameters.
Oral consent was obtained from each patient or a first-degree
relative, as the investigations were carried out under the standard
care procedure for this poorly characterized disease, in accordance
with the recommendations of the Committee for Clinical Research
of the GHSR. In France, written consent is mandatory only if the
medical treatments or the products used are not standard for the
diagnosis, treatment, or monitoring (art. 88-II, law 2004–806,
Journal Officiel, 08/11/2004; art. 31-I, law 2006–450, Journal Officiel,
04/19/2006). The information was given in French or in Creole
with the help of a translator when necessary.
Chikungunya is known to evolve in successive phases: first, a
viremic acute phase that lasts around 5 days, followed by a post-
viremic acute phase defined by a negative CHIKV RT-PCR,
presence of anti-CHIKV IgM antibodies but absence of IgG, that
lasts about a week before the appearance of anti CHIKV IgG [5].
Please note that this chronology only applies to patients originating
from area where CHIKV has not circulated previously, as it is the
case in La Re ´union. CHIKV-specific IgM and IgG antibodies
were detected by capture enzyme-linked immuno-sorbent assay
(ELISA) [6] and CHIKV-specific IgG antibodies by ELISA
developed at the French National Reference Centre for Arbovirus
(Institut Pasteur, Lyon, France) and automated with an EtiMax
3000 apparatus (DiaSorinH, Italy). The cut-off values for IgGs and
IgMs were determined from a series of 30 negative sera collected
in La Re ´union before the epidemic. A one-step TaqManH real
time quantitative RT-PCR was performed in serum samples using
the Light Cycler 2.0H (Roche Diagnostics). The assay sensitivity
for serum specimen was 350 copies per mL [7]. The patients
enrolled in the study were separated into two groups: Group A,
patients with Chikungunya, Group B, patients without Chikungu-
nya (negative RT-PCR and negative IgM anti CHIKV). In Group
A the patients were in the acute infection phase (RT-PCR + or
CHIKV Specific IgM + and IgG -). Within Group A, two
subgroups were defined: Group A1, patients with viremia (RT-
PCR+) and Group A2, patients without viremia. Whether the
patients in the acute infection phase (Group A) had been
hospitalized or not was used as a severity criterion.
Patients with positive anti-CHIKV IgG (i.e. that had been
infected with CHIKV previously) were excluded from the study.
The study subjects were tested for other agents susceptible of
causing fever and arthralgia. These include dengue and malaria
(present in other islands of this area of the Indian Ocean) as well as
leptospirosis, a prevalent infection in Reunion Island [8]. If
patients had travelled during the previous months in areas
endemic for malaria, a blood smear was performed. If patients
had travelled during the previous ten days, anti-dengue IgM and
dengue RT-PCR assays were performed. Leptospirosis diagnosis
using microagglutination and PCR assays were performed in the
presence of clinical signs evocative of leptospirosis, such as
jaundice.
Groups were compared using Chi-square or Fisher’s exact test,
when appropriate. Clinical and biological continuous parameters
were compared with the Mann-Whitney test. Averages and
standard deviation were calculated. A P value ,0.05 was con-
sidered statistically significant.
In order to rationalize the choice of clinical and biological data
for bivariate analysis, we looked for the sign with the highest
correlation with a given group; the Yule coefficient was used to
measure the strength of the link between the two variables (illness/
sign). A Yule coefficient between 0.7 and 1 was considered as a
very close link and 0.5–0.69 as a close link.
Results
During the study (1
st March 2006 - 31
st May 2006), 9,656
patients were admitted at the ED; 274 displayed febrile arthralgia
and were included in the study (Figure 1). Because their virological
data were missing, 8 patients had to be excluded. A CHIKV
viremia was present in 180 patients (Group A1) and absent in 86
patients. Anti-CHIKV IgM were present in 40 of these 86
patients; among these 40 patients, 34 had negative anti-CHIKV
IgG, and were in immediate post-viremic phase (Group A2). The
remaining 46 patients had no CHIKV infection (Group B).
Among all patients admitted to the ED during the study, 2.21%
were acutely infected by CHIKV and 1.86% were viremic. In
acutely CHIKV-infected patients with fever and arthralgia (Group
A), the positive predictive value of the presence of these two signs
for CHIKV acute infection was 82.3%.
Clinical features in Group A1 patients (Tables 1 to 5)
In Group A1, the average age did not significantly differ
between men and women. Co-morbidity was more common in
women (72.6 vs. 56.3%; p,0.05), particularly high blood pressure
(50.0 vs. 33.3%; p,0.05) and diabetes mellitus (33.3 vs. 16.6%;
p,0.05). Co-morbidity was more frequent in patients of 65 years
and over (97.4 vs. 39.4%; p,0.001). No case of leptospirosis,
dengue or malaria was diagnosed in this group.
Most patients presented to the ED during the first 3 days after
the onset of symptoms: 18.3% on the 1
st day, 41.1% on the 2
nd
day, 18.3% on the 3
rd day, and 10.0% on 4
th day. The onset of
symptoms was often described as abrupt, without prodromic
phase. The highest body temperatures were recorded in patients
who consulted within the 2 days that followed the onset of
symptoms (1
st day: 39.360.8uC; 2
nd day: 39.260.9uC; 3
rd day:
Chikungunya Infection
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th day: 38.960.9uC; 5
th day: 38.460.8uC; 1
st day-
2
nd day vs. 5
th day: p,0.05).
Data on osteoligamentous pain were available for 171 patients.
The 9 remaining patients were disoriented, either acutely or
chronically in the context of Alzheimer’s disease, and although
they complained from arthralgia, they were unable to describe
them further. The joint symptoms were most often characterized
by bilateral and symmetrical arthralgia (n=165; 96.5%). In few
cases, only 2 to 3 joints were affected (n=4; 2.3%), and only two
patients (1.2%) suffered from monoarthralgia. Impairment of the
finger joints was more frequent in women than men (66.7 vs.
47.9%; p,0.01). Nineteen patients (10.5%) suffered from pain
along previous bone fractures or ligaments injuries (tendinopathy,
Achilles’ tendon rupture) as well as increased arthrosic pain.
Clinical examination revealed pain along ligament insertions
(pubalgia, sternocleidomastoid and occipital insertions) in 3
patients (1.6%). Talalgia were observed in 24 patients (14.0%).
Joint inflammatory signs were rare (n=2; 1.1%) and peri-articular
swellings were more frequent in women than men (36.9 vs. 15.6%;
p,0.01).
Exanthema was either morbilliform, roseola-like, or more rarely
maculopapular. An erysipela aspect of the lower limbs was
reported in two patients (1.1%). Hemorrhagic signs were
extremely rare and were not associated with clotting abnormalities
or major thrombocytopenia. Uncommon neurological symptoms
included cutaneous dysesthesia (n=7; 3.9%) mostly of the sole of
the feet, hallucinations (n=2; 1.1%), paresthesia in the ulnar nerve
territory (n=1; 0.6%). Three patients (1.7%) presented with
convulsion: one patient was epileptic, another one exhibited
frequent comitial crises as stroke sequelae, and the last one suffered
from alcohol withdrawal.
Figure 1. Patients entering the emergency department and displaying the clinical signs associated with Chikungunya.
doi:10.1371/journal.pone.0007603.g001
Table 1. Demographic data.
Group A1
(n=180)
Group A2
(n=34)
Group B
(n=46)
Age 55.7621.7 54.5619,8 40.2621.9 ***
Range 15–96 17–89 16–93
Age $ 65 years old 76 (42.2%) 17 (50.0%) 7 (15.2%) **
Gender-ratio H/F 1,14 0.62 0.92
Comorbidity 115 (63.9%) 24 (70.6%) 18 (39.1%) **
- High blood pressure 74 (41.1%) 15 (62.5%) 3 (16.7%)
- Ischaemic heart
disease
23 (12.8%) 3 (12.5%) 0 (0.0%)
- Cardiac failure 17 (9.4%) 0 (0.0%) 1 (5.6%)
- Diabetes mellitus 44 (24.4%) 8 (33.3%) 3 (16.7%)
- Dyslipidemia 27 (15.0%) 3 (12.5%) 1 (5.6%)
- Obesity 12 (6.7%) 1 (2.9%) 1 (5.6%)
- Pulmonary pathology 21 (11.7%) 2 (5.9%) 2 (11.2%)
- Renal failure 15 (8.3%) 4 (16.7%) 0 (0.0%)
- Cerebro-vascular
accident
14 (7.8%) 4 (16.7%) 1 (5.6%)
- Epilepsy 14 (7.8%) 0 (0.0%) 3 (16.7%)
Group A1: RT PCR CHIKV positive patients. Group A2: RT PCR CHIKV
negative, IgM anti CHIKV positive, IgG anti CHIKV negative patients. Group
B: RT PCR CHIKV negative, IgM anti CHIKV negative, IgG anti CHIKV negative
patients.
Group A1 vs. Group A2:
¤¤¤ p,0.001,
¤¤ p,0.01,
¤ p,0,05.
Group A1 vs. Group B: *** p,0.001, ** p,0.01, * p,0,05.
Average, standard deviation, percentage in parenthesis are indicated.
doi:10.1371/journal.pone.0007603.t001
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decompensated a pre-existing cardiac insufficiency. Chest pain
was associated with pericarditis (n=2; 1.1%), acute coronary
syndrome (n=4; 2.2%), and myocarditis (n=2; 1.1%). The
registered cardiac arrhythmias (atrial fibrillation n=4, ventricular
extra systole n=2) were pre-existing conditions. Dyspnoea was
observed in 17 patients (9.4%), who were older than the average
age (71 year-old) and affected with respiratory or cardiac disorders
or complications (acute pneumopathy). Two patients of 15 and 18
year-old complained from abdominal pain and displayed clinical
signs of mesenteric lymphadenitis associated with peripheral
adenopathies.
Biological parameters in Group A1 patients (Table 6)
The blood platelet counts were lower for patients examined
on 5
th day (134,143633,354/mm
3) than for patients examined
on 1
st day (195,813651,859/mm
3;p ,0.01) or 2
nd day
(183,068653,996/mm
3;p ,0.05). During the viremic phase, the
average blood lymphocytes values were under the normal range,
without significant difference compared to the onset of symptoms.
A significant difference for the blood biological parameters
between genders was found for platelets (men 161,298649,050/
mm
3; women 189,000659,838/mm
3;p ,0.01), creatinine (men
117.4660.9 mmol/L; women 104.1684.5 mmol/L; p,0.001),
alanine aminotransferase (men 31.8622.4 UI/L; women
38.86128.4 UI/L; p,0.01) and creatine phosphokinase (men
3616874 UI/L; women 275.06696.0 UI/L; p,0.01).
Viral load was significantly higher in patients with comorbidity
than those without (2.29 10
6611.9 10
6 vs. 3.04 10
567.48 10
5
copies/mL; p,0.05). Viral load was also significantly higher in
patients 65 year-old and older than in patients less than 65 year-
old (3.86 10
5611.99 10
5 vs. 3.19 10
6614.55 10
6 copies/mL;
p,0.001).
Hospitalized patients in Group A
Sixty-nine patients (32.2%) were hospitalized. Two patients (83
and 73 year-old) died while they were hospitalized because of a
nosocomial Pseudomonas aeruginosa associated pneumopathy with
septicemia in one case and a coronary insufficiency in the other.
The hospitalized patients were older (p,0.001) and had higher
Table 2. Clinical signs.
Group A1 (n=180) Group A2 (n=34) Group B (n=46)
Number of days between onset
of symptoms and consultation 1.861.9 6.263.7
¤¤¤ 2.962.5 **
Range 0–12 1–16 0–11
Body temperature 39.160,86 37.960.6
¤¤¤ 38.461.1 ***
Body temperature $ 40uC 35 (19.4%) 0 (0.0%)
¤ 6 (13.0%)
Chill 23 (12.8%) 3 (8.8%) 5 (10.9%)
Myalgia 106 (58.9%) 20 (58.8%) 31 (67.4%)
Headache 126 (70.0%) 20 (58.8%) 36 (78.3%)
Skin rash 86 (47.8%) 23 (67.7%) 13 (28.3%) *
Adenopathy 16 (8.9%) 10 (29.4%)
¤¤ 3 (6.5%)
Pruritus 25 (13.9%) 14 (41.2%)
¤¤¤ 7 (15.2%)
Periarticular edemas 46 (25.6%) 15 (44.1%)
¤ 5 (10.9%)
Conjonctival hyperhemia 41(22.8%) 6 (17.7%) 6 (13.0%)
Digestive signs 114 (63.3%) 29 (85.3%)
¤ 37 (80.4%) *
- Nausea 67 (58.8%) 20 (69.0%) 27 (73.0%)
- Vomiting 49 (43.0%) 11 (37.9%) 22 (59.5%)
- Diarrhea 33 (28.9%) 11 (37.9%) 13 (35.1%)
- Anorexia 80 (70.2%) 25 (86.2%) 23 (62.2%)
- Dysgueusia 46 (40.4%) 17 (58.6%) 13 (35.1%)
- Abdominal pain 36 (31.6%) 5 (17.2%) 15 (40.5%)
Bleeding (gingivorrhagia, epistaxis) 2 (1.1%) 3 (8.8%)
¤ 1 (2.2%)
Asthenia 159 (88.3%) 31 (91.2%) 33 (71.7%) *
Lipothymia, vertigo 20 (11.1%) 4 (11.8%) 5 (10.9%)
Fainting 9 (5.0%) 0 (0.0%) 2 (4.3%)
Mental confusion 12 (6.7%) 3(8.8%) 1 (2.2%)
Attention deficit disorder 11 (6.1%) 2 (5.9%) 0 (0.0%)
Dry cough 14 (7.8%) 0 (0.0%) 5 (10.9%)
Group A1: RT PCR CHIKV positive patients. Group A2: RT PCR CHIKV negative, IgM anti CHIKV positive, IgG anti CHIKV negative patients. Group B: RT PCR CHIKV
negative, IgM anti CHIKV negative, IgG anti CHIKV negative patients.
Group A1 vs Group A2:
¤¤¤ p,0.001,
¤¤ p,0.01,
¤ p,0,05.
Group A1 vs. Group B: *** p,0.001, ** p,0.01, * p,0,05.
Average, standard deviation, percentage in parenthesis are indicated.
doi:10.1371/journal.pone.0007603.t002
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ones, these two factors being linked (p,0.01). Clinically, the
hospitalized patients did not differ from the non-hospitalized ones
except for periarticular oedemas, metacarpo-phalangeal joints and
feet arthralgia (p,0.05). The blood levels of urea, C-reactive
protein, creatinine phosphokinase, ASAT were significantly higher
(p,0.01) for hospitalized patients. In Group A1, the viral load was
significantly higher in hospitalized patients than in non-hospital-
ized patients (p,0.05).
Age over 65 was the factor most associated with severity (Yule
coefficient 0.78, sensitivity 74.6%, specificity 73.0%, positive
predictive value 57.9% negative predictive value 85.6%).
Clinical parameters in CHIKV uninfected patients with
febrile arthralgia (Group B)
The diagnoses in Group B differed, depending on whether the
patients had to be hospitalized or not. For non-hospitalized patients
(n=33), suspicion of CHIKV infection was the diagnosis most
frequentlymentioned but notconfirmed biologicallylateron (n=25)
(no alternative diagnosis was later obtained); other diagnoses were
malaria (n=2), pyelonephritis (n=4), gastroenteritis (n=1), phar-
yngitis (n=1). Among hospitalized patients (n=13), diagnoses were
pneumopathy (n=4), pyelonephritis (n=3), leptospirosis (n=2),
gastroenteritis (n=1), migraine (n=1), fulminant hepatitis of
unknown origin (n=1), microcrystalline arthropathy (n=1).
Comparison between groups of patients
Acutely CHIKV-infected patients (Group A) vs. patients without CHIKV
infection (Group B) – Clinical data are reported in the tables 1 to 5. A
total leukocyte blood count lower than 7.400/mm
3 was closely
associated with CHIKV infection (Yule coefficient 0.63, sensitivity
88.7%, specificity 36.4%, positive predictive value 80.4% negative
predictive value 52,2%).
Viremic (Group A1) vs. post-viremic (Group A2) CHIKV infected patients
– During the CHIKV acute period, there was a significant
difference between viremic (Group A1) and post-viremic (Group
A2) (Tables 2, 5 & 6). Lymphopenia (,1,000/mm
3) was very
closely associated with Group A1 (Yule coefficient 0.82, sensitivity
86.1%, specificity 61.8%, positive predictive value 92.3%, negative
predictive value 45.7%).
Viremic acute phase CHIKV infected patients (Group A1) vs. patients
without CHIKV infection (Group B) – Significant clinical and
Table 3. Arthralgia location.
Group A1 (n=171) Group A2 (n=31) Group B (n=42)
Upper limbs 155 (90.6%) 26 (83.9%) 36 (85.7%)
- Interphalangian joints 90 (52.6%) 16 (51.6%) 17 (40.5%)
- Metacarpo-phalangeal joints 81 (47.4%) 19 (62.2%) 12 (28.6%)
- Wrists 121 (59.7%) 23 (74.2%) 21 (50.0%) *
- Elbows 81 (47.4%) 14 (45.2%) 12 (28.6%)
- Shoulders 86 (50.3%) 17 (54.8%) 23 (57.1%)
Lower limbs 161 (94.1%) 29 (93.4%) 40 (95.2%)
- Feet 83 (48.5%) 18 (58.1%) 10 (23.8%) **
- Ankles 130 (76.0%) 26 (83.9%) 28 (66.7%)
- Knees 130 (76.0%) 25 (80.6%) 27 (64.3%)
- Hips 29 (17.0%) 2 (6.5%) 7 (16.7%)
Rachis 79 (46.2%) 14 (45.2%) 25 (59.5%)
Sternocostal joints 37 (21.6%) 5 (16.1%) 11 (26.2%)
Temporomandibular 3 (1.8%) 1 (3.2%) 1 (2.4%)
Large joints 169 (98.8%) 30 (96.8%) 40 (95.2%)
Small joints 128 (74.8%) 23 (74.2%) 26 (61.9%)
Group A1: RT PCR CHIKV positive patients. Group A2: RT PCR CHIKV negative, IgM anti CHIKV positive, IgG anti CHIKV negative patients. Group B: RT PCR CHIKV
negative, IgM anti CHIKV negative, IgG anti CHIKV negative patients.
Group A1 vs. Group A2:
¤¤¤ p,0.001,
¤¤ p,0.01,
¤ p,0,05.
Group A1 vs. Group B: *** p,0.001, ** p,0.01, * p,0,05.
Average, standard deviation, percentage in parenthesis are indicated.
doi:10.1371/journal.pone.0007603.t003
Table 4. Periarticular oedemas.
Group A1 (n=180) Group A2 (n=34) Group B (n=46)
Number 46 (25.6%) 15 (44.1%)? 5 (10.9%)
Location
- Fingers 22 (47.8%) 6 (40.0%) 3 (60.0%)
- Wrists 12 (26.1%) 5 (33.3%) 2 (40.0%)
- Elbows 1 (2.2%) 0 (0.0%) 0 (0.0%)
- Feet/
Toes
10 (21.7%) 3 (20.0%) 1 (20.0%)
- Ankles 31 (67.4%) 8 (53.3%) 1 (20.0%)
- Knees 4 (8.7%) 0 (0.0%) 0 (0.0%)
Group A1: RT PCR CHIKV positive patients. Group A2: RT PCR CHIKV
negative, IgM anti CHIKV positive, IgG anti CHIKV negative patients. Group
B: RT PCR CHIKV negative, IgM anti CHIKV negative, IgG anti CHIKV negative
patients.
Group A1 vs. Group A2:
¤¤¤ p,0.001,
¤¤ p,0.01,
¤ p,0,05.
Group A1 vs. Group B: *** p,0.001, ** p,0.01, * p,0,05.
Average, standard deviation, percentage in parenthesis are indicated.
doi:10.1371/journal.pone.0007603.t004
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the Tables 1, 2 & 6. Lymphopenia (,1,000/mm
3) was very closely
related to Group A1 (Yule coefficient 0.72, sensitivity 86.1%,
specificity 50.0%, positive predictive value 87.1% negative
predictive value 47.9%).
Discussion
We carried out a prospective study of the clinical and biological
features characterizing the acute viremic and post-viremic phases
of human Chikungunnya infection in patients referred to the ED
for febrile athralgia. The patients without Chikungunya entering
the ED with fever and arthralgia during the study were used as a
control group. The monthly numbers of newly admitted patients
with CHIKV viremia in our study were consistent with the
estimated incidence in La Re ´union [4] (March 2006 32,500, April
11,800, May 5,300). The percentages of viremic patients were
stable along the study and represented 0.5% of the total estimated
new cases in the Island in March, 0.45% in April and 0.45% in
May. Consequently, the newly admitted viremic patients at the
ED are representative of the epidemic. Yet, this study does not
take into account asymptomatic infections, but they are thought to
represent an extremely low proportion (5%) [3] when compared to
other arbovirosis such as dengue (80%) [9,10].
To our knowledge, this is the first prospective study on the
clinical and biological aspects of acute Chikungunya infections in
adults with differentiation between the viremic and non-viremic
phases during an outbreak. Previously published clinical and
biological data were obtained from retrospective analyses, usually
in the absence of virological confirmation of acute infection.
Several studies have used anti-CHIKV IgM as an acute phase
criterion but they are still present in more than 50% of patients a
year after the onset of the disease [5]. Simon et al. conducted a
prospective observational clinical study during the early stages of
Chikungunya infections (within 10 days of the disease onset) but
did not differentiate between the viremic and non-viremic phases
[11]. In addition, they included in their study data from a
retrospective questionnaire completed by patients examined 10
days after the onset of symptoms. Recent retrospective studies
reviewing cases that occurred in the Indian Ocean were published.
Taubitz et al. described clinical and biological results for 20
travellers admitted in their department 2 to 73 days after the onset
of symptoms [12]. Borgherini et al. published early biological and
clinical features for 157 adult patients during the outbreak on
Reunion Island [13]. Borgherini’s study displays the biases
inherent to retrospective surveys. In particular, the patient’s
selection and data collection processes did not include frequent
clinical signs such as myalgia. This study also differs from previous
works since its patients constitute an unbiased representative
sample of the population enrolling at the ED over a continuous
three-month period, and describes the clinical and biological
features of the viremic and post-viremic phases of the acute
CHIKV infection, as assessed by RT-PCR and IgM assays in 216
consecutive patients.
Moreover, most of these retrospective studies were carried out
in countries where co-infections with arboviruses such as Dengue
Table 5. Cutaneomucosal signs.
Group A1 (n=180) Group A2 (n=34) Group B (n=46)
Exanthem 86 (47.8%) 23 (67.7%) 13 (28.3%) *
Diffuse exanthem 16 (8.9%) 11 (32.4%)
¤¤¤ 1 (2.2%)
Exanthem with healthy skin intervals 70 (38.9%) 12 (35.3%)
¤¤¤ 12 (26.1%)
- Topography
- Face 26 (37.1%) 3 (25.0%) 4 (30.8%)
- Neck 26 (37.1%) 3 (25.0%) 2 (15.4%)
- Trunk 45 (64.3%) 8 (66.7%) 7 (53.9%)
- Arms 28 (40.0%) 5 (41.7%) 4 (30.8%)
- Forearms 19 (27.1%) 3 (25.0%) 1 (7.7%)
- Hands 6 (8.6%) 0 (0.0%) 1 (7.7%)
- Thighs 9 (12.9%) 7 (58.3%)
¤¤ 4 (30.8%)
- Legs 18 (25.7%) 5 (41.7%) 2 (15.4%)
- Feet 5 (7.1%) 0 (0.0%) 1 (7.7%)
Purpura 4 (2.2%) 3 (8.8%) 0 (0.0%)
Vesicles/bubbles 3 (1.7%) 0 (0.0%) 0 (0.0%)
Pruritus 25 (13,9%) 14 (41.2
%) ¤¤¤ 7 (15.2%)
Pruritus whitout skin lesions 8 (4.4%) 2 (5.9%) 6 (13.0%) *
Cutaneous hyperesthesia 7 (3.9%) 0 (0.0%) 0 (0.0%)
Conjunctival hyperhemia 41 (22.8%) 6 (17.7%) 6 (13.0%)
Mouth ulcers 0 (0.0%) 1 (2.9%) 0 (0.0%)
Pharyngitis 2 (1.1%) 0 (0.0%) 1 (7.7%)
Group A1: RT PCR CHIKV positive patients. Group A2: RT PCR CHIKV negative, IgM anti CHIKV positive, IgG anti CHIKV negative patients. Group B: RT PCR CHIKV
negative, IgM anti CHIKV negative, IgG anti CHIKV negative patients.
Group A1 vs. Group A2:
¤¤¤ p,0.001,
¤¤ p,0.01,
¤ p,0,05.
Group A1 vs. Group B: *** p,0.001, ** p,0.01, * p,0,05.
Average, standard deviation, percentage in parenthesis are indicated.
doi:10.1371/journal.pone.0007603.t005
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for co-infections. No case of dengue fever was diagnosed in our
study, and no cases of dengue fever or other arbovirosis was
reported in 2006 in La Re ´union, therefore reinforcing the
specificity of our findings. Malaria and leptospirosis were not
diagnosed in our patients infected with CHIKV. We found rare
and benign hemorrhagic signs, in contrast to what previously
reported in India and Southeast Asia —areas where Dengue is
endemo-epidemic— where CHIKV was incriminated in haemor-
rhagic fever outbreaks [15]. Hemorrhagic signs in other studies
among adults were probably attributable to co-infection, especially
with dengue or yellow fever viruses, even if Asian CHIKV
genotypes differ from the one responsible for the Indian Ocean
outbreak, which is of East African origin [16]. During the outbreak
in La Re ´union, hemorrhagic signs were described in our
prospective study of neonatal Chikungunya infection [17] and
thrombocytopenia and haemostasis troubles were also common in
the neonatal context.
Since 1953, the classical clinical features of acute Chikungunya
associate the triad fever, arthralgia and inconstant skin rash [18].
We showed here that fever is concomitant of viremia, with the
highest temperatures in the 2 days that follow the onset of the
symptoms.
Arthralgia is key to the clinical diagnosis of acute CHIKV
infection. However, forms with secondary arthralgia or without
arthralgia have been described in Asian studies [19]. In a random
sample of the population of La Re ´union during the post-epidemic
phase, 9.7% of proven Chikungunya cases (i.e. with a positive
serology) reported no arthralgia, including the 5% asymptomatic
forms [3]. In our study, the presence of arthralgia was mandatory for
inclusion, and asymptomatic forms were obviously not referred to
the ED. CHIKV-associated arthralgia have not been characterized
in detail so far [20,21]. While in most cases, bilateral and
symmetrical polyarthralgiawerereported (although sometimes more
intense on one side), we observed two cases of monoarticular
arthralgiaoftheankle.Werecorded rarelocationsofarthralgia,such
as of the temporo-mandibular joint, and forms that had never been
reported in previous descriptions such as chondrocostal arthralgia,
affecting up to 20% of the patients, and hip arthralgia (17%).
CHIKV also appeared to revive pain along former fractures lines
and ligament injuries, and clinical examination revealed entesopa-
thies and talalgia, which had never been described previously.
The frequency of skin rash ranged from 20% to 85% [18,22]. In
our study, about half of the patients presented a skin rash, generally
arising during the first three days of infection. Our study matches
former studies in the location and aspect of the skin lesions but differs
bythe existence ofvesicular and bullousforms as wellas erysipela-like
lesions of the lower limbs. By mean of RT-PCR, we could document
the specificity of these skin manifestations by amplifying the viral
genome within this vesicular fluid (our unpublished data).
Our study illustrates the variety of the other clinical manifes-
tations that can be associated with CHIKV infection. Yet, these
Table 6. Biological parameters.
Groupe A1 (n=180) Groupe A2 (n=34) Groupe B (n=46)
Platelets 174288655962 173735662235 193444692057
(150000–500000/mm
3)
# (38000–355000) (46000–330000) (26000–579000)
Leucocytes 5,43162,139 5,19962,554 7,42963,640 ***
(4500–13500/mm
3)
# (1,900–14,800) (1,400–12,400) (1,700–16,600)
Lymphocytes 6086314 1,0906481
¤¤ ¤ 1,1416747 ***
(1000–4000/mm
3)
# (100–2,360) (300–2,500) (200–3,400)
Urea 6.864.9 6.163.2 5.864.401
(2.5–7.5 mmol/L)
# (1.6–37.0) (2.6–16.0) (2.3–27.6)
Creatinine 111,1673,1 104.26100.9 89.3648.4 **
(50–100 mmol/L)
# (40.0–604.0) (53.0–661.0) (35.0–328.0)
CRP 55.9650.4 30.5649.7
¤¤¤ 73.36108.5
(,2.5 mg/L)
# (0.0–351.0) 0.0–267.0) (0.0–492.0)
Calcemia 2.2860.14 2.3160.12 2.3360.15 **
(2.25–2.65 mmol/L)
# (1.8–2.7) (2.05–2.66) (1.96–2.75)
ASAT 55.06164.0 53.2642.3 333.261952.8
(,45 UI/L)
# (12.0–2177.0) (16.0–195.0) (13.0–13140.0)
ALAT 35.2689.7 39.5629.9
¤ 122.96651.4
(,65 UI/L)
# (7.0–1189.0) (11.0–125.0) (8.0–4394.0)
CK 320.66794.3 334.66630.7 291.66542.7
(,210 UI/L)
# (22.0–7608.0) (25.0–2901.0) (28.0–3209.0)
Lipase 42.5629.3 42.3619.9 32.0626.2 **
(,60 UI/L)
# (9.0–202.0) (15.0–101.1) (9.0–180.0)
Group A1: RT PCR CHIKV positive patients. Group A2: RT PCR CHIKV negative, IgM anti CHIKV positive, IgG anti CHIKV negative patients. Group B: RT PCR CHIKV
negative, IgM anti CHIKV negative, IgG anti CHIKV negative patients.
Group A1 vs. Group A2:
¤¤¤ p,0.001,
¤¤ p,0.01,
¤ p,0,05.
Group A1 vs. Group B: *** p,0.001, ** p,0.01, * p,0,05.
Average, standard deviation, percentage in parenthesis are indicated.
#Physiological ranges.
doi:10.1371/journal.pone.0007603.t006
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other viral infections. Some of these clinical symptoms may also
correspond to decompensation of underlying conditions and to
iatrogenic effects (e.g. paracetamol and hepatitis, non-steroidal
anti-inflammatory and kidney failure).
Severe clinical forms with neurological [23,24] and cardiac
involvements [25,26] have also been reported in the literature. In
1973, Obeyesekere [25] described the first cases of acute
pericarditis and myocardiopathy associated with CHIKV, based
on serology. Thus, CHIKV may, as other viruses, trigger
pericarditis and myocarditis. Lemant et al. [27], in a retrospective
survey of CHIKV-infected patients admitted to intensive care,
reported a case of fatal fulminant myocarditis for which analysis of
post-mortem myocardial tissue samples pathological examination
demonstrated the presence of cytoplasmic viral inclusions in
myocytes. Cardiac complications and myocarditis have also been
described in infected newborns on the Island of La Re ´union
[17,28].
Neurological symptoms (vertigo or confusion) observed in our
study may be attributable to fever and dehydration. However, a
neurotropism of CHIKV has several times been suspected
[14,29,30]. Mazaud [30] reported a case of acute encephalitic
syndrome, and Deller [29] described the onset of vertigo and a
vestibular syndrome. In India, Carey [14] observed important
neurological after-effects. In La Re ´union, severe cases of meningo-
encephalopathy among adults [27] and newborns [28], and acute
polyradiculoneuritis were also attributed to CHIKV [24].
Consistent with these clinical observations, we have shown, in
an animal model for Chikungunya, that CHIKV may disseminate
to the central nervous system, and infect the meninges and the
ependymal tissue [31].
Mazaud[30]observedbiological similaritiesbetween dengueand
chikungunya. Indeed, it was reported that these two arbovirosis are
associated with brief leukoneutropenia (3 to 4 days) and thrombo-
cytopenia [30]. According to this author, leukoneutropenia and
thrombocytopenia have great orientation value in favour of these
two arboviroses. In other studies, no leukopenia was reported [19].
In contrast to these retrospective studies in which the differential
diagnosis between dengue and chikungunya could not be precisely
assessed, we found in our series that 38% of patients were
leukopenic and that in Group A1, lymphopenia dominated and
was very closely associated with viremia; for 85% of the patients
lymphocyte count was lower or equal to 1,000/mm
3 and for 50% of
the patients the level was lower than 500/mm
3. Thrombocytopenia
was found in 42% of the patients, but to moderate levels, between
100,000 and 150,000/mm
3.
Cases of severe acute hepatitis occurring during the CHIKV
infection have already been described in La Re ´union. While it was
suggested that this virus may target the liver –a finding confirmed
in our animal model in the first hours of infection–, acute hepatitis
seems to be mainly promoted by chronic ethylism, denutrition and
paracetamol toxicity [32]. The serum ASAT level was increased
for 32% of the patients as opposed to only 7% for the ALAT.
These results suggest that the increase in the serum level of ASAT
was partially related to muscle injury, with 60% of the patients
with increased ASAT also presented a rhabdomyolysis.
When using the two cardinal clinical signs in acute phase, fever
and arthralgia, for the diagnosis, we found a specificity of 99,6%
and a positive predictive value of 84.6%. Leucopenia and
lymphopenia could be used to aid in the diagnosis of CHIKV
infection in acute phase, but not for formal diagnosis. The positive
predictive values for these parameters, found in our work, are
inappropriate. Indeed, the high number of CHIKV-infected
patients compared to controls tends to artificially raise the positive
predictive values and decrease the negative predictive value. So,
leucopenia/lymphopenia values are suggested as only one
parameter that could be a part of a diagnosis algorithm. Other
mosquito-transmitted viruses with overlapping geographic distri-
butions, specifically Dengue Fever, can have similar hematologic
abnormalities. However because of the risk of transmission of the
Chikungunya fever in European countries free of Dengue Fever,
these hematologic abnormalities are of interest and value.
Factors influencing disease severity are dominated by age and
comorbidities. However, these two criteria are strongly linked.
Among viremic patients, age under 65 was an excellent predictor
of non-severity (severity negative predictive value 85.6%), with
only functional impotence due to lower limbs pain and inability to
walk leading to hospitalization in this group.
Little is known about the pathophysiology of CHIKV infection,
in contrast to better characterized alphaviruses such as Sindbis and
Ross River viruses. Sourisseau et al. [33] have reported that
CHIKV replicates in various human cultured cells, such as
epithelial and endothelial cells, primary fibroblasts and, to a lesser
extent, macrophages. CHIKV replication induces a significant
cytopathic effect, and may also lead to apoptosis. CHIKV
replication is significantly inhibited by type I IFNs, suggesting a
prominent role of the innate immune system in the control of the
infection and the rapid decline of viremia before the appearance of
neutralizing antibodies during the acute phase of infection. It has
also been reported that CHIKV may also infect muscle satellite
cells in humans [34]. In a mouse model of chikungunya, we have
shown that fibroblasts of tissues in which seats symptoms in
humans (muscles, joints, skin), are the target cells of CHIKV [31],
these findings matching viral tropism in human as assessed by
CHIKV immunolabeling of infected human tissues. The infection
of muscles and joints, which contain nerve endings may account
for the nociceptive pain observed in the course of human acute
infection. The functional neurological manifestations complicating
the course of acute CHIKV infection may reflect CHIKV
dissemination to the central nervous system, consistent with the
positive CHIKV RT-PCR in the cerebrospinal fluid of these
patients and the observation that CHIKV infect the choroid
plexuses, meninges and the ependyma in the mouse animal model
[31].
The worldwide distribution of Aedes albopictus and the adaptation
of the virus to this vector [16,35] may cause the emergence and
spread of epidemic CHIKV in North and South America and in
European countries, as illustrated recently in Ital [36]. In addition
to the basic original information it provides on this little known
disease, this study should be of help to clinicians confronted to a
CHIKV outbreak, for clinical and logistic management of acutely
infected patients presenting at the emergency room.
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